Mistletoe therapy in addition to standard immunotherapy in patients with non-small cell lung cancer indicates improved survival rates
Immunotherapy with PD-1/PD-L1 inhibitors has significantly improved the survival rates of patients with metastatic non-small cell lung cancer (NSCLC). Results of a real-world data study (RWD) investigating the addition of Viscum album L. (VA) to chemotherapy have shown an association with improved survival in patients with NSCLC - regardless of age, degreee of metastasis, performance status, lifestyle or oncological treatment. The mechanisms may include synergistic modulations of the immune response by PD-1/PD-L1 inhibitors and VA. These findings may underline the clinical impact of add-on VA. However, the results should be taken with caution due to the observational and non-randomised study design. The study has been published open access in Cancers:
https://doi.org/10.3390/cancers16081609.